4//SEC Filing
Valliant John 4
Accession 0000950170-24-002291
CIK 0001805890other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:41 AM ET
Size
7.6 KB
Accession
0000950170-24-002291
Insider Transaction Report
Form 4
Valliant John
DirectorChief Executive Officer
Transactions
- Award
Restricted Stock Units
2024-01-04+192,200→ 192,200 total→ Common Stock (192,200 underlying) - Award
Stock Option (Right to Buy)
2024-01-04+320,400→ 320,400 totalExercise: $8.44Exp: 2034-01-04→ Common Stock (320,400 underlying)
Footnotes (3)
- [F1]This option vests in 48 equal monthly installments beginning on February 4, 2024.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration.
- [F3]The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
Related Parties
1- filerCIK 0001813574
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:41 AM ET
- Size
- 7.6 KB